Vertex tests shorter Incivek therapy in patient subset

Vertex Pharmaceuticals ($VRTX) will put its Incivek hepatitis C treatment through a trial to determine whether combination therapy for the disease could be shortened to 12 weeks in patients with a particular genetic variation associated with a stronger and faster response to antiviral therapy. Vertex release

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.